Aims: Merkel cell carcinoma represents poorly differentiated neuroendocrine carcinoma of cutaneous origin. In most studies, the vast majority of Merkel cell carcinomas are Merkel cell polyomavirus (MCPyV)-associated. SV40 polyomavirus immunohistochemistry is typically used in the diagnosis of other polyomavirus-associated diseases, including tubulointerstitial nephritis and progressive multifocal leukoencephalopathy, given cross-reactivity with BK and JC polyomaviruses. MCPyV-specific immunohistochemistry is commercially available, but, if antibodies against SV40 also cross-reacted with MCPyV, that would be advantageous from a resource-utilisation perspective. Methods and results: Tissue microarrays were constructed from 39 Merkel cell carcinomas, 24 smallcell lung carcinomas, and 18 extrapulmonary visceral small-cell carcinomas. SV40 large T antigen immunohistochemistry (clone PAb416) was performed; MCPyV large T antigen immunohistochemistry (clone CM2B4) had been previously performed. UniProt was used to compare the amino acid sequences of the SV40, BK, JC and MCPyV large T antigens, focusing on areas recognised by the PAb416 and CM2B4 clones. SV40 immunohistochemistry was negative in all tumours; MCPyV immunohistochemistry was positive in 38% of Merkel cell carcinomas and in 0% of non-cutaneous poorly differentiated neuroendocrine carcinomas. UniProt analysis revealed a high degree of similarity between SV40, BK, and JC viruses in the region recognised by PAb416. There was less homology between SV40 and MCPyV in this region, which was also interrupted by two long stretches of amino acids unique to MCPyV. The CM2B4 clone recognises a unique epitope in one of these stretches. Conclusions: The PAb416 antibody against the SV40 large T antigen does not cross-react with MCPyV large T antigen, and thus does not label Merkel cell carcinoma.
A monoclonal antibody against SV40 large T antigen (PAb416) does not label Merkel cell carcinoma
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Introduction
Merkel cell carcinoma represents poorly differentiated neuroendocrine carcinoma of cutaneous origin.
1,2 The disease is uncommon, although it is sharply increasing in incidence, with the 1600 cases diagnosed in the USA each year representing a 400% increase over the last 25 years. 3 Its associated mortality of ≥33% exceeds that of melanoma. 4 Given clinical associations with older age and immunosuppression, investigators hypothesised a possible infectious aetiology. Utilising an approach they dubbed 'digital transcriptome subtraction', in which diseased tissue is subjected to high-throughput sequencing, alignment and 'subtraction' of known human sequences, and alignment of residual sequences to known infectious agents, Feng et al. identified a novel polyomavirus, which they named Merkel cell polyomavirus (MCPyV). 5 They showed that the virus is clonally integrated into most Merkel cell carcinomas, and that the virus undergoes mutations, which are critical to oncogenesis, that truncate its large T antigen. 6 The same group developed a mouse monoclonal antibody (CM2B4) against a unique 14 amino acid sequence in exon 2 of the large T antigen. 7 The antibody subsequently became commercially available, and was shown to be a sensitive and specific marker for Merkel cell carcinoma.
8 CM2B4 was available from only a single vendor. After we had optimised staining in our research laboratory but before CM2B4 had been adopted for use in our clinical laboratory, we learned that the vendor had reached an agreement (May 2016) with the US Department of Agriculture (USDA) regarding alleged violations of the Animal Welfare Act (AWA) over a time period from 2012 to 2015.
9 Our diagnostic immunohistochemistry laboratory (along with many others) worked to immediately find alternatives for all assays utilising primary antibodies from this vendor.
MCPyV is one of 13 known human polyomaviruses (eight have been discovered subsequent to MCPyV). Polyomavirus infection is ubiquitous and typically asymptomatic. The most familiar human polyomaviruses are BK virus and JC virus. BK (and occasionally JC) virus causes tubulointerstitial nephritis iñ 5% of kidney transplant patients (and rarely in other settings), whereas JC virus is the aetiological agent in progressive multifocal leukoencephalopathy, usually in AIDS patients. Polyomavirus immunohistochemistry is used in urine cytology to confirm the presence of viral cytopathic effect in 'decoy cells' (the presence of which may precede the development of nephropathy), is the gold standard for the diagnosis of BK virus nephropathy in transplant kidney core biopsies, and is typically used in brain biopsies or at autopsy to support a diagnosis of progressive multifocal leukoencephalopathy. Antibodies against the monkey polyomavirus SV40, which is known to have a high degree of sequence homology with BK and JC viruses, are typically utilised clinically.
Given known cross-reactivity of monoclonal antibodies against SV40 with other human polyomaviruses, we hypothesised that they might also label Merkel cell carcinoma, which would obviate the need to use CM2B4, desirable from both resource-utilisation and ethical perspectives. We demonstrate here that the most commonly utilised anti-SV40 immunostain does not, in fact, label Merkel cell carcinoma, and that this appears to be related to large T antigen sequence divergence in the antigenic region of interest.
Materials and methods
Poorly differentiated neuroendocrine carcinomas were identified from the surgical pathology archives of the University of Iowa Hospitals and Clinics, including Merkel cell carcinoma and small-cell carcinoma of lung or extrapulmonary visceral origin. Original glass slides from 81 tumours were reviewed, the diagnosis was confirmed, and a 'best tumour block' was identified. Tissue microarrays (TMAs) were constructed using the Manual Tissue Arrayer MTA-1 (Beecher Instruments, Sun Prairie, WI, USA), with tumours arrayed as triplicate 1-mm cores.
SV40 large T antigen immunohistochemistry on an Autostainer Link 48 (Agilent Dako, Santa Clara, CA, USA) was performed on 4-lm-thick tissue sections after deparaffinisation, rehydration, and PT Link (Agilent Dako) heat-induced epitope retrieval in Target Retrieval Solution (pH 9; Agilent Dako), with the mouse monoclonal antibody PAb416 (Calbiochem/ EMD Millipore, Temecula, CA, USA; 1:200 dilution; 30-min incubation) and the polymer-based EnVision FLEX+ detection system (Agilent Dako; 30-min incubation). BK polyomavirus nephropathy served as the positive control. MCPyV large T antigen immunohistochemistry (mouse monoclonal CM2B4; 1:200 dilution) had been performed previously, with a whole section of Merkel cell carcinoma serving as the positive control.
10 SV40 and CM2B4 immunostains were considered to be positive if there was any staining.
We subsequently explored SV40, BK, JC and MCPyV amino acid homology in the regions recognised by the SV40 and MCPyV large T antigen primary antibodies. PAb416 recognises an epitope within amino acids 83-128 of the SV40 large T antigen, 11 whereas CM2B4 was raised against amino acids 116-129 of the MCPyV large T antigen. 7 The UniProtKB protein knowledgebase was queried for the amino acid sequences of the relevant polyomavirus large T antigens and then compared by use of the UniProt Align tool (http://www. uniprot.org/). 12 This research was conducted with University of Iowa Institutional Review Board approval.
Results

SV40 large T antigen immunohistochemistry was negative in all 39
Merkel cell carcinomas tested, as well as in 24 and 18 small-cell carcinomas of lung and extrapulmonary visceral origin. CM2B4 immunohistochemistry had been positive in 15 of 39 (38%) Merkel cell carcinomas and in 0 (0%) of the 42 visceral small-cell carcinomas (Figure 1) .
In the 46 amino acid stretch recognised by the PAb416 monoclonal antibody, BK and JC viruses showed 70% amino acid identity and 91% identity or similarity to SV40. MCPyV showed 41% identity and 74% identity or similarity to SV40; in addition, areas of homology within the 46 amino acid SV40 sequence were interrupted by stretches of 110 and 66 amino acids unique to the MCPyV large T antigen. The CM2B4 antibody was raised against a peptide based on a 14 amino acid sequence contained within that 110 amino acid stretch, and so would not be expected to cross-react with these other polyomaviruses.
Discussion
Although antibodies purportedly specific to various early or late antigens of BK and JC viruses are commercially available, 'pan-polyomavirus' immunohistochemistry with antibodies against SV40, especially against its large T antigen, is most commonly utilised in diagnostic pathology. Among 30 monoclonal antibodies against the SV40 large T antigen evaluated in a series of cells and tissues transformed or infected with JC virus, PAb416 performed best. 13 Although many of the antibodies gave strong signals in an SV40-transformed cell line, only PAb416 and PAb108 also labelled a JC virus-transformed cell line, a JC-induced hamster tumour xenograft, and human progressive multifocal leukoencephalopathy tissue, with the former giving a much stronger signal. In the Banff Initiative for Quality Assurance in Transplantation study on reproducibility of polyomavirus immunohistochemistry in kidney allografts, 68% of 60 participating laboratories utilised the PAb416 clone, which was associated with more reproducible results than those seen in the minority of laboratories using alternative antibodies.
14 As demonstrated in our study, however, SV40 large T antigen immunohistochemistry with this clone will not detect MCPyV large T antigen.
Our results corroborate those of Shuda et al. 7 In the initial study that described the generation and evaluation of the CM2B4 monoclonal antibody, they performed immunofluorescence and immunoblotting experiments with MCPyV, JC and BK virus large T antigen-transfected human embryonic kidney 293 cells. Whereas CM2B4 was specific for MCPyV large T antigen, PAb416 recognised JC and BK but not MCPyV large T antigen. They also examined 22 other SV40 large T antigen monoclonal antibodies by immunoblotting, none of which reacted with MCPyV large T antigen: PAb101, PAb108, PAb204, PAb210, PAb211, PAb216, PAb405, PAb407, PAb409, PAb419, PAb423, PAb430, PAb431, PAb433, PAb441, PAb442, PAb602, PAb603, PAb605, PAb606, PAb901, and PAb902.
MCPyV is generally detected in 80% of Merkel cell carcinomas by polymerase chain reaction, and at a similar rate by immunohistochemistry, although the frequency has been significantly lower in a few outlier studies. 8 Notably, in one Australian study, CM2B4 immunohistochemistry was positive in only 21% (19/89) of pure Merkel cell carcinomas. 15 The finding that all Merkel cell carcinomas are not MCPyV-positive and that the frequency of MCPyV positivity appeared to be much lower in Australian patients led investigators to hypothesise that Merkel cell carcinoma actually represented two diseases, one attributable to viral oncogenesis and another to ultraviolet radiation-induced damage. This hypothesis has subsequently been supported by the results of nextgeneration sequencing experiments, which have highlighted the mutational landscape of MCPyV-positive versus MCPyV-negative cases (Table 1) . 16, 17 The frequency of CM2B4 positivity in our cohort (38%) is lower than in other Western cohorts. Although this is perhaps due, at least in part, to unique characteristics of our patient population (Iowa is distinctly agricultural and thus sun-exposed, although it would never be mistaken for Australia), it is quite possible that the actual frequency of MCPyV positivity is higher, as a result of false negatives attributable to a suboptimal immunohistochemical staining protocol or the use of TMAs rather than whole sections. Although these concerns led us to hold off on publishing an initial abstract, we chose to include this finding here as evidence that at least some of our Merkel cell carcinomas are virus-associated, and thus, if PAb416 cross-reacted with MCPyV large T antigen, at least some of the Merkel cell carcinomas should have been positive.
As mentioned in the introduction, from the time when it became commercially available, CM2B4 was offered by only a single vendor. That vendor had run afoul of the Animal and Plant Health Inspection Service of the USDA on numerous occasions, which culminated in a settlement with the US government in which the vendor agreed to pay a $3.5 million fine, had its AWA license revoked, and was ordered to cease activities as a 'research facility' (as defined by the AWA). Despite this agreement, the company is still in business. On close reading of the Animal Welfare Act, whereas the term 'animal' includes dogs, cats, primates, guinea pigs, hamsters, and rabbits, it specifically excludes 'birds, rats of the genus Rattus, and mice of the genus Mus, bred for use in research'.
The ability to identify MCPyV has diagnostic, appears to have prognostic and, in the future, may have predictive implications. Although an immunopanel including thyroid transcription factor 1 (TTF-1) and cytokeratin (CK) 20 is generally useful in distinguishing small-cell lung carcinoma (TTF-1+/CK20À) from Merkel cell carcinoma (TTF-1À/CK20+), smallcell carcinomas of extrapulmonary visceral origin variably express TTF-1 and occasionally express CK20, leading to diagnostic ambiguity. Although, in our experience, CK20 is typically expressed by only 5-10% of extrapulmonary visceral small-cell carcinomas overall, primary parotid tumours are well known to be TTF-1À/CK20+ (60-75% of cases). 8 The distinction of a primary small-cell carcinoma of salivary gland origin from Merkel cell carcinoma, which is a diagnostic dilemma two or three times a year in our practice, is the diagnostic setting in which the availability of MCPyV immunohistochemistry would be most desirable. Entirely analogous to head and neck squamous cell carcinoma, in which there are viral (high-risk human papillomavirus) and non-viral tumours, MCPyV positivity appears to connote a more favourable prognosis, possibly because of a lower mutational burden and/or to intrinsic viral tumour-induced immunity. In a Finnish populationbased study, with a MCPyV positivity rate of 80%, the 5-year survival rates of patients with virus- associated and non-virus-associated tumours were 45% and 13%, respectively. 18 Given distinct tumourassociated immune complements and genetic profiles, MCPyV status will probably be incorporated into future clinical trial designs.
Conclusions
Most Merkel cell carcinomas are polyomavirus-associated. The ability to detect MCPyV has diagnostic and prognostic implications. BK and JC viruses are readily detectable with SV40 large T antigen immunohistochemistry. MCPyV large T antigen immunohistochemistry is commercially available, but, if SV40 immunohistochemistry could be used instead, it would be advantageous from a resource-utilisation perspective. Furthermore, ethical concerns have been raised surrounding the single vendor from which CM2B4 was commercially available. We have shown here that SV40 large T antigen immunohistochemistry with the PAb416 mouse monoclonal antibody does not label Merkel cell carcinoma. We have also shown that this is probably attributable to large T antigen amino acid sequence divergence between SV40 and MCPyV. Subsequent to our performance of this study, CM2B4 has been offered by a second vendor (Merck/Millipore Sigma), and we plan to use it in our diagnostic laboratory.
